hide
Free keywords:
-
Abstract:
Antidepressant drug discovery and development have been put on hold by
many pharmaceutical companies. The main reason for this is the negative
efficacy studies with novel specific drugs. Here I argue that the main
obstacles are the absence of gene tests and biomarkers as an integral
part of a diagnostic process. Further, too much emphasis has been put on
validating drug candidates in animal models of psychiatric disorders. A
more rapid transfer of drug candidates into human research is necessary
to overcome current obstacles that prevent the discovery of
next-generation antidepressants.
